Table 3

Common terminology used in REMAP trials

TermDefinitionExamples
FactorThe mutually exclusive interventions, categorised within domains, to which a patient can be randomised.

  • Pirfenidone

  • Nintedanib

  • New antifibrotic

  • Control

DomainA distinct category of mutually exclusive interventions called factors; patients can be randomised to receive a factor from a domain for which they are eligible.

  • Antifibrotic

  • Immunomodulatory

  • Senolytic

  • Corticosteroids

RegimenThe collection of factors that a patient is randomised to across domains; patients receive one unique factor from each domain for which they are eligible.

  • Pirfenidone, mycophenolate, metformin and corticosteroid

  • Nintedanib, control (no immunomodulation), metformin and control (no corticosteroid)

StratumBaseline disease characterisation that defines which domain(s) a patient is potentially eligible to participate in; strata can be used for stratified randomisation and strata-specific analyses.

  • IPF

  • Non-IPF fILD

  • fILD, fibrotic interstitial lung disease; IPF, idiopathic pulmonary fibrosis; REMAP, Randomised Embedded Multifactorial Adaptive Platform.